Success Metrics

Clinical Success Rate

100.0%

Based on 1 completed trials

Completion Rate

100%(1/1)

Active Trials

2(50%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_2

75%

Ph phase_1

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

1(25.0%)

Phase 2Efficacy & side effects

3(75.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Completed(1)

Detailed Status

Recruiting2

Completed1

Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 11 (25.0%)

Phase 23 (75.0%)

Trials by Status

completed125%

not_yet_recruiting125%

recruiting250%

Recent Activity

2 active trials

Showing 4 of 4

completedphase_2

Does Psilocybin Require Psychedelic Effects to Treat Depression?

NCT05710237

not_yet_recruitingphase_2

Subjective Experience Following Psilocybin

NCT06768944

recruitingphase_1

Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects

NCT07490353

recruitingphase_2

Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)

NCT06512220

Clinical Trials (4)

Showing 4 of 4 trials

NCT05710237Phase 2

Does Psilocybin Require Psychedelic Effects to Treat Depression?

Completed

NCT06768944Phase 2

Subjective Experience Following Psilocybin

Not Yet Recruiting

NCT07490353Phase 1

Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects

Recruiting

NCT06512220Phase 2

Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)

Recruiting

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4